NL-OMON46980已完成2 期
A multi-centre, phase II, randomized, double-blind, placebo-controlled study to investigate efficacy and safety of sevuparin infusion for the management of acute vaso-occlusive crisis (VOC) in subjects with sickle-cell disease (SCD) - TVOC01
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 64（—）
入选标准
- •1. Sign a written informed consent.
- •2. Male or female, age 12 - 50 years.
- •3. Diagnosis of sickle cell disease, types HbSS, HbSC, Hb O Arab, HbSß0-thalassemia or HbSß+-thalassemia (SCD type to be confirmed by HPLC confirmed or other method of comparable reliability durin the study, if confirmation is not available at time of inclusion).
- •4. Subjects admitted for an acute, painful VOC to be treated / or treated with parenteral opiod analgesia at the time of admission. VOC is defined as an episode of pain that led to a clinic or emergency department visit, and cannot be explained except by SCD. Please note: Study treatment should start as soon as possible and at the latest within 24 hours from the time of the decision to hospitalize the subject.
- •5. Expectancy of the need for hospitalization for at least 48 hours.
- •6. Be at least 1 year postmenopausal, surgically sterile, or if WOCBP use an effective method of birth control during study drug administration and one month following treatment completion.
排除标准
- •1. Severe hepatic failure/disease, or liver enzyme tests (AST and ALT) above 2 times the upper limit of normal (ULN) range, or clinically significant impairment of liver function due to HBV, HCV or other liver diseases.
- •2. Conjugated (direct) bilirubin 3 fold above ULN.
- •3. History of clinically significant bleeding in vital organs (not due to relevant trauma), or pathological bleeding.
- •4. Current clinically significant bleeding, as judged by the investigator
- •5. Current use of ASA, anti-platelet therapy, anticoagulant therapy and prophylactic and therapeutic LMWH or un-fractioned heparin.
- •6. APTT above normal range, and INR above 1.4.
- •7. A platelet count <75,000/µL.
- •8. BMI >35
- •9. Subjects with more than 5 hospitalizations for VOC during the last 6 months (to exclude subjects with exacerbations of chronic pain rather than true vaso-occlusion).
- •10. Evidence of acute SCD complications other than VOC at screening (CVA, ACS, multi-organ failure).
- •11. The use of strong opiods for >3 consecutive days during the last 15 days before presenting to the hospital.
- •12. History of chronic drug abuse.
- •13. Renal dysfunction (GFR< 60 ml/min)
- •14. Known infection (positivity) with HIV, and active infection with HBV or HCV.
- •15. Significant ECG abnormality including QTcf > 450 msec (for details please see Section 8.3.3.)
- •16. History of a clinically significant drug allergy to heparin, LMWH*s, or Sevuparin.
- •17. Use of any investigational agent during the 30 days prior to the first dose.
- •18. For females: pregnancy, lactating or intention of becoming pregnant within the next 40 days.
- •19. Evidence of clinically significant disorders that might interfere with the study aim or safety of the subject, as judged by the Investigator: e.g. neurological, psychiatric (depression, psychosis or schizophrenia), cardiovascular (including arrhythmia), pulmonary, metabolic, gastrointestinal, endocrine diseases, coagulation or malignancies.
研究者
相似试验
进行中（未招募）
不适用
A placebo controlled clinical study to determine how omalizumab treats chronic idiopathic urticaria (CIU) in patients with symptoms despite treatment with antihistamines (H1)MedDRA version: 14.1Level: LLTClassification code 10009159Term: Chronic urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersChronic Idiopathic UrticariaEUCTR2011-004216-31-DEovartis Pharma Services AG
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-FRILTOO PHARMA100
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-PTILTOO PHARMA100
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-ATILTOO PHARMA100
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-ITILTOO PHARMA100